Company: XAIR
Filing Date: 2025-02-10
Form Type: 10-Q
Source: 0001493152-25-005678
Chunk: 97

Company: Beyond Air, Inc.
Filing Date: 2025-02-10
Form: 10-Q
Item: Part II, Item 8
Chunk 97
---
 the nine months ended December 31, 2024:

    (in thousands) 
    Beyond Air  
    Beyond Cancer  
    Total 
  
    Revenue 
    $2,553  
    $-  
    $2,553 
  
    Net loss for the nine months ended December 31, 2024 
    $(31,293) 
    $(9,123) 
    $(40,416)

The
following table summarizes segment financial performance by business segment for the three months ended December 31, 2024:

    (in thousands) 
    Beyond Air  
    Beyond Cancer  
    Total 
  
    Revenue 
    $1,072  
    $-  
    $1,072 
  
    Net loss for the three months ended December 31, 2024 
    $(11,833) 
    $(1,500) 
    $(13,333)

The
following table summarizes segment financial performance by business segment for the nine months ended December 31, 2023:

    (in thousands) 
    Beyond Air  
    Beyond Cancer  
    Total 

    Revenue 
    $689  
    $-  
    $689 
  
    Net loss for the nine months ended December 31, 2023 
    $(33,721) 
    $(16,018) 
    $(49,739)

The
following table summarizes segment financial performance by business segment for the three months ended December 31, 2023:

    (in thousands) 
    Beyond Air  
    Beyond Cancer  
    Total 
  
    Revenue 
    $391  
    $-  
    $391 
  
    Net loss for the three months ended December 31, 2023 
    $(12,065) 
    $(5,193) 
    $(17,258)
  
    Net loss  
    $(12,065) 
    $(5,193) 
    $(17,258)

Research
and Development

Research
and development expenses are charged to the unaudited condensed consolidated statements of operations and comprehensive loss as incurred.
Research and development expenses include salaries, benefits, stock-based compensation and costs incurred by outside laboratories, manufacturers,
clinical research organizations, consultants, and accredited facilities in connection with preclinical studies and clinical trials. Research
and development expenses are partially offset by the benefit of tax incentive payments for qualified research and development expenditures
from the Australian tax authority (“AU Tax